Indication
As an add-on to standard therapy for the treatment of generalised myasthenia gravis (gMG) in adult patients who are anti‑acetylcholine receptor (AChR) antibody positive.
Medicine details
- Medicine name:
- zilucoplan (Zilbrysq)
- SMC ID:
- SMC2955
- Pharmaceutical company
- UCB Pharma Ltd
- BNF chapter
- Central nervous system
- Submission type
- Resubmission
- Publication due date:
- 10 August 2026
- SMC meeting date:
- 07 July 2026
- Patient group submission deadline:
- TBC